GRIS-PEG

Take this medication by mouth as directed by your doctor. For the best absorption, it is best taken with or after a meal containing a moderate amount of fat. Talk to your doctor or pharmacist about specific dietary instructions, especially if you are on a low-fat diet.

The dosage is based on your medical condition and response to therapy. In children, dosage is also based on weight. The length of treatment depends on the type of infection you have. It may take several weeks to months to complete treatment for infections of the scalp, feet, and body. Nail infections may require several months to a year or longer to treat.

Antifungal medications work best when the amount of medicine in your body is kept at a constant level. Therefore, take this drug at evenly spaced intervals.

Continue to take this medication for the full prescribed length of treatment even if symptoms improve after a few days. Stopping the medication too early may allow the fungus to continue to grow, which may result in a relapse of the infection.

Inform your doctor if your condition persists or worsens.

Gris-PEG® Tablets contain ultramicrosize crystals of griseofulvin, an antibiotic derived from a species of Penicillium.

Each Gris-PEG tablet contains:
Active Ingredient: griseofulvin ultramicrosize ... 125 mg
Inactive Ingredients: colloidal silicon dioxide, lactose, magnesium stearate, methylcellulose, methylparaben, polyethylene glycol 400 and 8000, povidone, and titanium dioxide.

OR
Active Ingredient: griseofulvin ultramicrosize ... 250 mg
Inactive Ingredients: colloidal silicon dioxide, magnesium stearate, methylcellulose, methylparaben, polyethylene glycol 400 and 8000, povidone, sodium lauryl sulfate, and titanium dioxide.

Gris-PEG is contraindicated in patients with porphyria or hepatocellular failure and in individuals with a history of hypersensitivity to griseofulvin. Griseofulvin should not be prescribed to pregnant patients. Two cases of conjoined twins have been reported since 1977 in patients taking griseofulvin during the first trimester of pregnancy. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. There have been post marketing reports of severe skin reactions, and hepatotoxicity, that have been associated with griseofulvin use. When adverse reactions occur, they are most commonly of the hypersensitivity type such as skin rashes, uticaria, erythema multiforme-like drug reactions, and rarely, angioneurotic edema, and may necessitate withdrawal of therapy and appropriate countermeasures.